Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01759056 · ClinicalTrials.gov registry record · Phase 1
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
A Phase 1 study of Ulcerative Colitis, sponsored by Avaxia Biologics, Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 16
- Study locations
NCT01759056 is a Phase 1 study of Ulcerative Colitis that has completed, run by Avaxia Biologics, Incorporated. The registered enrollment target is 33 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower). The trial reports 16 study locations across 12 states.
The verdict
NCT01759056, a Phase 1 study of Ulcerative Colitis, has completed, sponsored by Avaxia Biologics, Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability as well as the pharmacodynamic effects of multiple doses of AVX-470 administered orally in patients with active ulcerative colitis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AVX 470
Study Locations (16)
Other
- Gastro-Enterologie - Ghent
- Gastro-enterologie - Leuven
- Semmelweis Egyetem - Budapest
- Debreceni Egyetem Orvos- és Egészségtudományi Centrum - Debrecen
- Kenézy Kórház Rendelöintézet Egészségügyi Szolgáltató Kft. - Debrecen
California
- Anaheim Clinical Trials - Anaheim
Colorado
- Rocky Mountain Gastroenterology Associates - Lakewood
Florida
- Shafran Gastroenterology Center - Winter Park
Maryland
- Chevy Chase Clinical Research - Chevy Chase
Michigan
- Clinical Research Institute of Michigan - Chesterfield
Missouri
- Center for Digestive and Liver Disease - Mexico
Ohio
- Remington-Davis, Inc. - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01759056
The ClinicalTrials.gov registry entry for NCT01759056 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower). The listed sponsor is Avaxia Biologics, Incorporated, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01759056 reports 16 study locations spanning 12 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT01759056 about?
NCT01759056 is a clinical study titled "Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis". The purpose of this study is to evaluate the safety and tolerability as well as the pharmacodynamic effects of multiple doses of AVX-470 administered orally in patients with active ulcerative colitis.
What is the current status of trial NCT01759056?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2013-02. Estimated completion is 2013-12.
What conditions does trial NCT01759056 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT01759056?
The interventions under investigation include: Placebo (DRUG), AVX 470 (DRUG).
Who is sponsoring clinical trial NCT01759056?
This trial is sponsored by Avaxia Biologics, Incorporated, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01759056 being conducted?
This trial has 16 study locations across California, Colorado, Florida, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Use of Butyrate Therapy in Pediatric Ulcerative Colitis
RECRUITING · Phase 1
-
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
RECRUITING · Phase 1
-
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
RECRUITING · Phase 1
-
CP101 for the Treatment of Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 1
-
Angiographic Delivery of AD-MSC for Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.